The report forecasts the global spine biologics market to grow at a CAGR of 2.07% during the period 2016-2020. To calculate the market size, we consider the revenue generated from the sales of the following:
Bone morphogenetic proteins (BMPs)
Demineralized bone matrix (DBM)
Synthetic bone grafts
According to the report, a key growth driver is the rising popularity of MI spinal and robot-assisted surgeries. The shift in preference to MI surgeries from open surgical method has led to the high adoption of spine biologics in MI spine surgeries. Traditional open surgeries can cause various post-operation complications such as pain, partially collapsed lungs, blood clots, fatigue, muscle atrophy, and infections.
Many medical facilities are conducting spinal fusion surgeries to repair the vertebrae and treat other spine diseases. Spine fusion surgery is performed to treat severe degeneration of the disc material in the spine by placing a bone graft, resulting in generation of a new bone that bridges the vertebrae.
Further, the report states that one challenge that could restrict market growth is complication associated with spinal surgeries. Sometimes the bones take longer to fuse (delayed union) and in some cases the bones do not fuse (non-union). This requires the need for a second surgery to allow healing of the bones.
Johnson & Johnson
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Spine biologics: An overview
PART 06: Market landscape
PART 07: Market segmentation by product
PART 08: Global spine biologics market by allograft
PART 09: Global spine biologics market by stem cells
PART 10: Global spine biologics market by BMP
PART 11: Global spine biologics market by DBM
PART 12: Global spine biologics market by synthetic bone grafts